What is driving the significant increase in Vertex's revenue and net income?

The primary driver of Vertex's substantial revenue and net income growth is the strong performance and market uptake of its triple combination regimen for cystic fibrosis, TRIKAFTA/KAFTRIO. This new therapy has significantly expanded the eligible patient population and is generating substantial product revenue, more than compensating for sales declines in older CF treatments as patients switch.

How is Vertex managing its research and development expenses given its pipeline expansion?

Vertex continues to invest significantly in R&D, with expenses increasing by 7% for the nine months ended September 30, 2020. This investment supports its core cystic fibrosis franchise, including label expansions and studies in younger age groups, as well as its diversification into new therapeutic areas such as genetic therapies, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney diseases. The company balances this investment with operational efficiencies, leading to a strong net income.

What is Vertex's liquidity position and how is it being managed?

Vertex maintains a very strong liquidity position, with $6.2 billion in cash, cash equivalents, and marketable securities as of September 30, 2020. This robust financial standing is supported by strong operating cash flows generated from product sales. The company also has access to significant revolving credit facilities and intends to use its existing cash and ongoing cash flows to fund its operations, R&D activities, and potential business development transactions.

What are Vertex's key areas of focus beyond cystic fibrosis?

Vertex is strategically diversifying its pipeline beyond cystic fibrosis. Key areas of focus include developing genetic therapies for sickle cell disease and beta-thalassemia in collaboration with CRISPR Therapeutics, treatments for alpha-1 antitrypsin deficiency, and therapies for APOL1-mediated kidney diseases. They are also advancing cell-based therapies for type 1 diabetes.

VRTX 10-Q Quarterly Report Q3 FY2020 — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals Inc. (VRTX) reported strong financial performance for the nine months ended September 30, 2020, with total revenues growing by 66% year-over-year to $4.58 billion. This growth was primarily driven by the successful launch and uptake of TRIKAFTA/KAFTRIO, their triple combination regimen for cystic fibrosis (CF), which significantly boosted product revenues. Net income saw a substantial increase of 255% to $2.11 billion, reflecting robust sales growth and improved operational efficiencies. The company continues to invest heavily in research and development, with a strong focus on expanding its CF franchise and diversifying into other therapeutic areas like alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, and genetic therapies for sickle cell disease and beta thalassemia. Despite increased R&D and SG&A expenses to support pipeline development and commercialization efforts, Vertex maintains a strong liquidity position with $6.2 billion in cash, cash equivalents, and marketable securities as of September 30, 2020.

Financial Highlights

52 data points

Beta

Revenue

$1.54B

0.9% Gross Margin

Net Income

$667.43M

0.4% Net Margin

EPS (Diluted)

$2.53

Total Assets

$11.30B

Cash & Equivalents

$5.36B

Free Cash Flow

$732.95M

Financial Statements

Beta

Revenue	$1.54B
Cost of Revenue	$186.18M
Gross Profit	$1.35B
R&D Expenses	$493.50M
SG&A Expenses	$184.55M
Operating Expenses	$866.03M
Operating Income	$672.24M
Interest Expense	$13.86M
Net Income	$667.43M
EPS (Basic)	$2.56
EPS (Diluted)	$2.53
Shares Outstanding (Basic)	260.39M
Shares Outstanding (Diluted)	264.08M

Key Highlights

1Total revenues increased by 66% to $4.58 billion for the nine months ended September 30, 2020, compared to the same period in 2019.
2Net income surged by 255% to $2.11 billion for the nine months ended September 30, 2020.
3Product revenues, driven by TRIKAFTA/KAFTRIO, increased significantly, more than offsetting declines in older CF medications as patients transitioned.
4Research and development expenses increased by 7% to $1.36 billion for the nine months ended September 30, 2020, reflecting continued investment in pipeline expansion beyond CF.
5The company ended the period with a strong liquidity position, holding $6.2 billion in cash, cash equivalents, and marketable securities.
6Vertex is actively pursuing label expansions for its CF medicines and progressing its pipeline in areas like genetic therapies for sickle cell disease and beta thalassemia.

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions